HRTX Q3 2022 Earnings — Heron Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

HRTXHeron Therapeutics, Inc.

$153M

Q3 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$27M+14.3% YoY

Gross Profit

$12M44.6% margin

Operating Income

-$42M-157.7% margin

Net Income

-$42M-157.8% margin

EPS (Diluted)

$-0.38

QoQ Revenue Growth

-3.9%

Cash Flow

Operating Cash Flow

-$37M

Free Cash Flow

-$37M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$272M

Total Liabilities

$250M

Stockholders' Equity

$22M

Cash & Equivalents

$50M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$27M	$23M	+14.3%
Gross Profit	$12M	$12M	-0.3%
Operating Income	-$42M	-$52M	+19.0%
Net Income	-$42M	-$52M	+20.0%

Revenue Segments

C I N V A N T I

$21M80%

Z Y N R E L E F

$3M10%

S U S T O L

$3M10%